Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Harvard Bioscience ( (HBIO) ) is now available.
On August 12, 2025, Harvard Bioscience, Inc. announced a retention letter agreement with Mark Frost, its Interim Chief Financial Officer, offering him a $100,000 cash bonus upon successful refinancing of the company’s existing term loan and senior revolving credit facility by March 15, 2026. This agreement replaces a previous $50,000 bonus offer and includes provisions for salary and benefits continuation if Mr. Frost’s employment is terminated without cause before the refinancing date, highlighting the company’s strategic focus on financial stability and leadership retention.
The most recent analyst rating on (HBIO) stock is a Buy with a $4.50 price target. To see the full list of analyst forecasts on Harvard Bioscience stock, see the HBIO Stock Forecast page.
Spark’s Take on HBIO Stock
According to Spark, TipRanks’ AI Analyst, HBIO is a Neutral.
The overall stock score for Harvard Bioscience is 53, reflecting significant financial challenges and valuation concerns. While there are positive signs in cash flow improvements and strategic leadership changes, the company’s profitability issues and credit concerns weigh heavily on the score. Technical indicators and earnings call sentiment provide some optimism, but the overall outlook remains cautious.
To see Spark’s full report on HBIO stock, click here.
More about Harvard Bioscience
Harvard Bioscience, Inc. operates in the life sciences industry, focusing on the development and manufacturing of scientific instruments, systems, and solutions that facilitate research and drug discovery.
Average Trading Volume: 12,111,506
Technical Sentiment Signal: Sell
Current Market Cap: $21.49M
Find detailed analytics on HBIO stock on TipRanks’ Stock Analysis page.